Nearly half of the world’s population suffers from some form of neurological condition ranging from simple migraines to Alzheimers. And yet in low-income countries, more than 75% of people needing neurological treatment cannot access care, according to a new World Health Organization report released on Tuesday, World Brain Day.  

The treatment gap – the difference between the number of people with a condition and those receiving treatment for it – is the combined result of misconceptions about neurological diseases, low diagnostic capacity and limited access to medicines.

“Most people with neurological disorders struggle to access the treatment they need for their conditions because these medicines do not reach them or are too expensive,” said Dévora Kestel, Director of WHO’s Department of Mental Health, Brain Health and Substance Use in a press statement. 

Should that change, “the impact of neurological disorders can be significantly decreased and quality of life improved.”

Using epilepsy and Parkinson’s disease as tracer conditions, the new WHO report identifies bottlenecks in existing treatments, particularly access to care in remote and rural areas.  

The report also advocates for more education about neurological disorders to reduce stigma. And it recommends that neurological treatments  be integrated more completely into the essential medicines lists (EMLs) of national authorities as well as WHO’s own recommended essential medicines listing.

Finally, local healthcare systems need to budget for procurement of such medications – while international donors and agencies consider how to make treatments more affordable – including through donor-supported funding. 

Treatment access, but also prevention programmes, “will take a whole of society approach, especially given that the whole of society is impacted either directly or indirectly by these diseases,” said Dr David Dodick, co-chair of World Brain Day, at a briefing Monday, just ahead of the WHO report launch.

Nearly half of the world’s population suffers from a neurological condition 

In 2021, almost half of the world’s population, or 3.4 billion individuals suffered from a neurological condition, including side effects from a stroke, Alzheimer’s disease, neonatal brain injury, or chronic migraines, according to the Institute for Health Metrics and Evaluation (IHME) data. 

But the burden is distributed unevenly, with over 80% of the deaths related to neurological conditions, as well as losses in healthy life years, occurring in low- and middle-income countries.

Neurological conditions are a leading cause of healthy life years lost (disability-adjusted life years, or DALYs) in 2021, ahead of cardiovascular diseases. In 2021, that amounted to a total of 443 million healthy life years lost due to a  chronic  illness, disability, or premature death.

Over the last three decades, DALYs associated with neurological conditions rose by 18% – and that is likely to increase further as a result of aging populations as well as lifestyle and environmental risks.

Over 80% of premature deaths from neurological conditions occurs in low- and middle-income countries – which have only 0.1 neurologist, on average, per 100,000 people. 

That is in comparison to 7.1 neurologists per 100,000 people in high-income countries, said Dodick.

On a more positive note, when diagnosis and treatment are available, then some 90% of strokes, 40% of dementia cases, and 30% of epilepsies are preventable. 

“We know what the modifiable risk factors are for some of the most prevalent and disabling neurological conditions, like stroke and Alzheimer’s disease, for example,” Dodick said.

Barriers to reaching global goals set out by WHA in 2022

The report identifies barriers limiting attainment of goals set by the World Health Assembly in 2022 to improve access to neurological care and treatment by 2031. 

The goals, laid out in the Intersectional global plan on epilepsy (IGAP), aim to have four out of five countries providing essential medicines and technologies to manage neurological disorders in primary health care settings within the coming decade. 

Even when treatment methods for neurological conditions are theoretically available, patients face many obstacles to accessing care. 

In African and Eastern Mediterranean regions, for instance, children with epilepsy are less likely to attend school because of the stigma surrounding the disorder. As the report shows, lack of knowledge about Parkinson’s and epilepsy, and exclusionary practices around people with those conditions, are common issues.

More regional manufacturing of medicines can bolster supply chains

The paucity of medicines available in pharmacies and clinics also was highlighted by country-level surveys included in the WHO report. 

In Ghana, for instance, out of 180 drug stores surveyed, levitiracetam, which is used to treat epilepsy, was available in only 50% of urban pharmacies and not at all in rural areas. Similarly, another epilepsy medicine, phenobarbital, was only available in roughly every second urban drug stores and in one in three rural pharmacies.

The report highlights the need for regional manufacturing of such medicines as well as more robust supply chains, overall, to ensure that such essential drugs are accessible. 

Consistent regulatory authorization of essential neurological medicines and ensuring their inclusion in national essential medicines lists, could also lead to more state financing support, improving treatment affordability.

Finally, the report also identifies the need for more specialised healthcare staff, particularly in rural areas, as well as more systematic data collection to improve surveillance. 

Neurological health access should be “inclusive and equitable”, also on the prevention level, said Prof. Tissa Wijeratne, Co-Chair, World Brain Day, during the webinar. “Access to preventative measures at community level, grassroot level, individual level, […] should be available to everybody across the world.”

Image Credits: WHO, IHME.